BioSpace

Disc’s Regulatory Comeback Plan for Rejected Drug Relies on Old FDA Leadership

Disc Medicine’s leadership tried to express optimism that its rare disease therapy bitopertin can be approved based on a Phase 3 trial set to begin shortly. However, analysts are worried that the ...
Seeking Alpha

Disc Medicine to Host Webinar with Key Opinion Leaders on Anemia of Myelofibrosis (MF)

WATERTOWN, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Seeking Alpha

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer

WATERTOWN, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
WFLA News Channel 8

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer

WATERTOWN, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
BioSpace

Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders

The FDA outright refuses to review Moderna’s mRNA-based flu vaccine as CBER director Vinay Prasad’s conduct is scrutinized; Disc Medicine receives an unexpected rejection, which Prasad may also have ...